Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

8.3%

1 terminated/withdrawn out of 12 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

25%

3 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

7(63.6%)

Phase 3

3(27.3%)

Phase 1

1(9.1%)

11Total

Phase 2(7)

Phase 3(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT06320353Phase 3Completed

Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma

Role: collaborator

NCT06307093Phase 1Completed

Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms

Role: collaborator

NCT05190991Phase 2Recruiting

Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever

Role: collaborator

NCT05092776Phase 2Active Not Recruiting

Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine

Role: collaborator

NCT06440746Phase 2Recruiting

Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Role: collaborator

NCT05107934Phase 2Suspended

Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis

Role: collaborator

NCT05432960Phase 3Withdrawn

Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)

Role: collaborator

NCT05673902Phase 3Active Not Recruiting

Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis

Role: collaborator

NCT04463251Phase 2Completed

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

Role: collaborator

NCT05196477Completed

Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection

Role: collaborator

NCT04692766Phase 2Completed

Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis

Role: collaborator

NCT04380519Phase 2Completed

Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)

Role: collaborator

All 12 trials loaded